ClinicalTrials.gg
CompletedNCT01072682Updated Mar 31, 2022Results posted

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

An interventional study of Selective cytopheretic device (SCD) in Acute Renal Failure, sponsored by SeaStar Medical. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by SeaStar Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Enrollment
157th of 237
35 · median 67
Started
2010
with 18 others
No phase
106 of 370
25 open now
Registered
41st of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 157th largest by enrollment of the 237 interventional ones that give a count, is one of 19 that started in 2010, is one of 106 with no phase, and was the 41st registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute renal failure (ARF).

Read the detailed description

Acute renal failure is a condition where the kidneys are not capable of producing adequate urine. Therefore, another way to remove waste from the body is needed to hopefully allow time for the kidneys to heal. One method of removing waste from the body is called Continuous Renal Replacement Therapy (CRRT) or variations of that therapy. This study will evaluate the safety of the device while it is connected to the CRRT tubing for up to 7 days. Patients will be followed up until day 60 following the treatment.

03

Conditions studied

  • Acute Renal Failure

Browse trials for

Keywords

  • Acute Renal Failure
  • Acute tubular necrosis
  • Continuous Renal Replacement Therapy
  • Selective cytopheretic device
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A patient, or legal representative, has signed a written form.
  2. Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma, Mixed, other).
  3. Age 18 to 80 years.
  4. Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
  5. Must be receiving and tolerating CRRT therapy for a minimum of 4 hours, but not longer than 24 hours.
  6. Expected to remain in the ICU for at least 96 hours after evaluation for enrollment.
  7. A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is defined as acute renal failure occurring in a setting of acute ischemic or nephrotoxic injury with oliguria (average \<20 mL/hr) for >6-12 hours or: an increase in serum creatinine ≥2 mg/dL (≥1.5 mg/dL in females) over a period of ≤4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies are excluded on clinical or other diagnostic grounds.)
  8. At least one non-renal organ failure (modified SOFA organ system score >2), as defined in Appendix A or presence (proven or suspected) of sepsis as defined in Appendix B.
  9. All patients must be able to tolerate regional citrate anticoagulation.

Exclusion criteria

Exclusion Criteria:

  1. to regional citrate anticoagulation.
  2. Irreversible brain damage based on available historical and clinical information.
  3. Presence of a renal transplant at any time.
  4. Non-candidacy for acute renal replacement therapy.
  5. Non-renal organ transplantation within six months of screening date.
  6. Presence of preexisting chronic renal failure prior to this episode of ARF. Preexisting chronic renal failure is defined as baseline serum creatinine >2.5 mg/dL (men), or >2.0 mg/dL (women).
  7. ARF occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity.
  8. which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy
  9. Chronic (e.g., AIDS, chronic therapy >20 mg/day prednisone equivalent on a chronic basis, or chemotherapy). The acute use of glucocorticoids is permissible
  10. Severe liver failure as documented by a Liver Failure Score >12.
  11. Do Not Resuscitate (DNR) status.
  12. Comfort measures only.
  13. Patient is moribund or for whom full supportive care is not indicated.
  14. Patient not expected to survive 28 days because of an irreversible medical condition.
  15. Any medical condition that the Investigator thinks may interfere with the study objectives.
  16. Physician refusal.
  17. Patient pregnant.
  18. Patient is a prisoner.
  19. Pre-morbid weight >128.5 kg.
  20. More than one hemodialysis treatment or longer than 24 hours since starting CRRT.
  21. count \<30,000/mm3.
  22. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and or samples are taken (NO TEST DEVICE OR DRUG USED) are allowed to participate.
  23. Use of any other drug or device within the previous 30 days.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    SCD

    Selective Cytopheretic Device

    Device: Selective cytopheretic device (SCD)

Interventions

  • DeviceSelective cytopheretic device (SCD)

    The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.

06

What researchers measure

Primary outcomes

  1. 60 Day Mortality

    Time frame: Day 60 following treatment end

  2. 60 Day Renal Recovery

    The criteria used to measure Renal Recovery requires the patient to be dependent free of CRRT and/or chronic dialysis.

    Time frame: Day 60 following treatment end

07

Results

Posted Mar 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneSCD Experimental Treatment Arm
Started35
Completed35
Not completed0

Outcome measures

Primary60 Day Mortality
Time frame:
Day 60 following treatment end
Reported as:
Count of participants · Participants
60 Day Mortality
ParticipantsSCD Experimental Treatment Arm
60 Day Mortality11
Primary60 Day Renal Recovery

The criteria used to measure Renal Recovery requires the patient to be dependent free of CRRT and/or chronic dialysis.

Time frame:
Day 60 following treatment end
Reported as:
Count of participants · Participants
60 Day Renal Recovery
ParticipantsSCD Experimental Treatment Arm
60 Day Renal Recovery24

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SCD Experimental Treatment Arm11/35 (31.4%)23/35 (65.7%)33/35 (94.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventSCD Experimental Treatment Arm
SepsisInfections and infestations3/35
Multi-System Organ FailureGeneral disorders3/35
PneumoniaInfections and infestations2/35
DICBlood and lymphatic system disorders2/35
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders2/35
Right Iliac Artery InjuryVascular disorders1/35
Complicated Abdominal WoundInfections and infestations1/35
ColitisGastrointestinal disorders1/35
Septic ShockInfections and infestations1/35
Cardiogenic ShockCardiac disorders1/35
Most frequent other events
Showing 10 of 34
Most frequent other events
EventSCD Experimental Treatment Arm
ThrombocytopeniaBlood and lymphatic system disorders9/35
HypotensionCardiac disorders7/35
AnemiaBlood and lymphatic system disorders7/35
HypophosphatemiaMetabolism and nutrition disorders5/35
LeukocytosisMetabolism and nutrition disorders4/35
NauseaGastrointestinal disorders4/35
CandidiasisInfections and infestations4/35
HypomagnesemiaMetabolism and nutrition disorders4/35
Atrial FibrillationCardiac disorders4/35
Rectal BleedGastrointestinal disorders4/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SCD Experimental Treatment Arm
<=18 years0
Between 18 and 65 years22
>=65 years13
Age, Continuous
Age, Continuous(years)SCD Experimental Treatment Arm
Mean56.3 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)SCD Experimental Treatment Arm
Female14
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SCD Experimental Treatment Arm
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American8
White25
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)SCD Experimental Treatment Arm
United States35
08

Study locations

7 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • University of California San Diego
    San Diego, California 92103, United States
  • Denver Nephrology
    Denver, Colorado 80230, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Hospital
    Chattanooga, Tennessee 37404, United States
  • University of Texas
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2022, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2010
First posted
Feb 22, 2010
Start
Feb 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Mar 9, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01072682
Lead sponsor
SeaStar Medical
Collaborators
Baim Institute for Clinical Research, Medtox
Responsible party
Sponsor
First posted
Feb 22, 2010
Start date
Feb 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Mar 9, 2022
Last update
Mar 31, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion